ArticleCell reports2021
Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed, 1 pooled it
20.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 1 synthesis or guideline pooled it, 205 citations in OpenAlex.
- The Use of Psychedelics in the Treatment of Adult ADHD: A Systematic and Mechanistic Review.International journal of molecular sciences · 2026Pooled it
- Acute and post-acute neurobehavioral responses to lysergic acid diethylamide in healthy subjects: a randomized controlled study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Trial
- Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder.Translational psychiatry · 2026Trial
- Deconstruction of lysergic acid diethylamide.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Prior trauma shapes the effects of psilocybin on stress sensitization in mice.Neuroscience letters · 2026Article
- Resetting the hippocampal buffer: a neurocognitive account of psychedelic therapy for anxiety-related psychopathology.Psychopharmacology · 2026Review
- Psychedelic 4-AcO-DMT attenuated looming-induced freezing behaviors by activating PrLMolecular psychiatry · 2026Article
- Psychedelics produce enduring enhancement of reward responsiveness in male rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Epigenetic landscapes of classical psychedelics and ketamine: molecular mechanisms of long-lasting neuromodulation.Molecular psychiatry · 2026Review
- The working lives of neuronal 5-HTRSC chemical biology · 2026Review
- Enhancing plasticity to treat depression and other central nervous system diseases using event-driven pharmacology.Journal of psychopharmacology (Oxford, England) · 2026Review
- Preclinical models for evaluating psychedelics in the treatment of major depressive disorder.British journal of pharmacology · 2026Review
- Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits.Human brain mapping · 2026Article
- Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care.Translational psychiatry · 2026Review
- Activity of Nonhallucinogenic Ibogalogs on Chemotherapy-Induced Peripheral Neuropathic Pain in Mice.ACS chemical neuroscience · 2026Article
- Stereoselective, sex-dependent 5-HTNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Learning as the unifying mechanism of psychedelic action.Journal of psychopharmacology (Oxford, England) · 2026Review
- Serotonergic modulation of excitatory synapse development and plasticity.Molecules and cells · 2026Review
- Article
- AI-derived therapeutic development of a serotonin receptor-targeting drug for the treatment of opioid use disorder.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Mario de la Fuente RevengaDepartment of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA; Virginia Institute of Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA 23298, USA.
Bohan ZhuDepartment of Chemical Engineering, Virginia Tech, Blacksburg, VA 24061, USA.
Christopher A GuevaraNash Family Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Lynette B NalerDepartment of Chemical Engineering, Virginia Tech, Blacksburg, VA 24061, USA.
Justin M SaundersDepartment of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA.
Zirui ZhouDepartment of Chemical Engineering, Virginia Tech, Blacksburg, VA 24061, USA.
Rudy ToneattiDepartment of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA.
Salvador SierraDepartment of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA.
Jennifer T WolstenholmeDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA.
Patrick M BeardsleyDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA; Center for Biomarker Research and Precision Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
George W HuntleyNash Family Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Chang LuDepartment of Chemical Engineering, Virginia Tech, Blacksburg, VA 24061, USA. Electronic address: changlu@vt.edu.
Javier González-MaesoDepartment of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA. Electronic address: javier.maeso@vcuhealth.org.
Virginia Commonwealth University · USVirginia Tech · USAllen Institute for Brain Science · US
Funding
Project 5 - Genetic architecture of alcohol use disorder using cross-trait genetic correlations and public next-generation sequencing studiesP50AA022537 · NIAAA · VIRGINIA COMMONWEALTH UNIVERSITY · PI JILL C BETTINGER · 2014 to 2026
$19.6MVCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Matthew Sean Halquist · 2014 to 2026
$13.8MStructure and function of the 5HT2A/mGluR2 complex in schizophreniaR01MH084894 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI Javier Gonzalez-Maeso · 2009 to 2026
$6.8MResearch Training: Psychiatric &Statistical GeneticsT32MH020030 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI HERMINE H MAES, MICHAEL CHURTON NEALE · 1999 to 2026
$6.7MTraining Program in NeuroscienceT32MH087004 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GEORGE W. HUNTLEY · 2009 to 2026
$4.0MImpact of human disease-causing mutation on striatal synaptic and behavioral plasticityR01NS107512 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BENSON, DEANNA L, HUNTLEY, GEORGE W. · 2019 to 2022
$2.1MPreclinical role of HDAC2 in mGlu2-dependent schizophrenia treatmentR01MH111940 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI GONZÁLEZ-MAESO, JAVIER · 2017 to 2021
$1.5MDroplet microfluidic technology for single-cell epigenomic and multi-omic profilingR01GM143940 · NIGMS · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI LU, CHANG · 2021 to 2024
$1.3MGut dysbiosis and 5-HT2A dysregulation in a preclinical schizophrenia modelF30MH116550 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI SAUNDERS, JUSTIN M · 2018 to 2021
$151kNIAAA NIH HHS P50 AA022537NIDA NIH HHS P30 DA033934NIGMS NIH HHS R01 GM143940NIMH NIH HHS F30 MH116550NIMH NIH HHS R01 MH084894NIMH NIH HHS R01 MH111940NIMH NIH HHS T32 MH020030NIMH NIH HHS T32 MH087004NINDS NIH HHS R01 NS107512
Abstract
Clinical evidence suggests that rapid and sustained antidepressant action can be attained with a single exposure to psychedelics. However, the biological substrates and key mediators of psychedelics' enduring action remain unknown. Here, we show that a single administration of the psychedelic DOI produces fast-acting effects on frontal cortex dendritic spine structure and acceleration of fear extinction via the 5-HT
Indexed as
AmphetaminesAnimalsBehavior, AnimalDendritic SpinesEpigenesis, GeneticEpigenomeEpigenomicsExtinction, PsychologicalFearFrontal LobeHallucinogensMaleMiceMice, 129 StrainMice, Inbred C57BLMice, Knockout4-iodo-2,5-dimethoxyphenylisopropylamineAmphetaminesHallucinogensHtr2a protein, mouseReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor Agonists5-HT2A receptordepressionepigenomicsGPCRhallucinogenspsychedelicspsychosisschizophreniaserotonin (5-HT)synaptic plasticity
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.